Articles tagged "Renal function"

2018 American Transplant Congress
Superior Renal Function with CNI-Free Everolimus over Standard CNI-Based Regimen: 18 Months Data from the Randomized, Multi-Center MANDELA Trial in De Novo Heart Transplant Recipients
M. J. Barten,¹ S. W. Hirt,¹ J. Garbade,¹ C. Bara,¹ A. Doesch,¹ C. Knosalla,¹ C. Grinninger,¹ J. Stypmann,¹ C. Sieder,² M. Junge,² U. Schulz.¹
¹Mandela Study Group, Germany; ²Novartis, Pharma, Germany.
Purpose: The MANDELA study (NCT00862979) was designed to assess the benefit on renal function of either CNI-free or CNI-minimized EVR-based regimen after early conversion of…
2018 American Transplant Congress
Long-Term Outcomes of Liver Transplantation in Patients with Pre-Transplant Renal Dysfunction Treated with Induction Therapy and Delayed Reduced De Novo Once-Daily Tacrolimus
M. Gastaca,¹ J. Bustamante,² A. Ventoso,¹ J. Fernandez,² P. Ruiz,¹ M. Testillano,² M. Prieto,¹ P. Salvador,² I. Palomares,¹ M. Senosiain,² M. Suarez,² A. Valdivieso.¹
¹Hepatobiliary Surgery and Liver Transplant Unit, Cruces University Hospital, Bilbao, Spain; ²Hepatology Unit, Cruces University Hospital, Bilbao, Spain.
AIM: To describe the long-term outcome of liver transplantation (LT) in patients with pre-transplant renal dysfunction treated with induction therapy and delayed reduced de novo…
2018 American Transplant Congress
Efficacy and Safety of Tocilizumab in Treatment of Acute Antibody Mediated Rejection
K. Venkatachalam, D. Reem, M. Andrew, R. Delos Santos, T. Alhamad.
Transplant Nephrology, Washington University, Saint Louis, MO; Transplant Nephrology, Ohio State University, Columbus, OH; Transplant Nephrology, Washington University, Saint Louis, MO; Transplant Nephrology, Washington University, Saint Louis, MO.
Antibody mediated rejection continues to be one of the most detrimental complications of kidney transplant. Multiple therapeutic strategies focused on B cell and/or HLA antibody…
2018 American Transplant Congress
Side Effect Profile of Everolimus in Liver Transplant Patients
F. Kumssa, O. Sadiq, M. Alimirah, R. Kaur, A. Patel, S-.M. Jafri.
Henry Ford Hospital, Detroit.
IntroductionUse of calcineurin inhibitors has been the mainstay of antirejection medications after liver transplant (LT). However, renal toxicity from these drugs remains troublesome. By comparison,…
2018 American Transplant Congress
Kidney Transplantation in ESKD Patients with a History of Sickle Cell Disease/Trait
A. Lee, G. Malat, M. Harhay, L. Levin, G. Xiao, S. Guy, D. Reich, K. Ranganna.
Department of Medicine, Division of Nephrology & Hypertension, Drexel University College of Medicine, Philadelphia, PA.
Introduction:Kidney transplantation in Sickle Cell Disease patients is fraught with complications, including increased risk of infection and thrombosis. We present long term outcomes of patients…
2018 American Transplant Congress
Evaluation of Clinical and Safety Outcomes Following Uncontrolled Tacrolimus Conversion in Adult Transplant Recipients
A. Lichvar,¹ S. Tremblay,² D. Naik,² E. King,⁴ A. Vinks,⁴ U. Christians,³ J. Lipscomb,⁴ R. Alloway.²
¹U of Illinois at Chicago, Chicago, IL; ²U of Cincinnati, Cincinnati, OH; ³U of Colorado, Denver, CO; ⁴Cincinnati Children's, Cincinnati, OH.
Background: Long-term studies with control groups are required to assess tacrolimus (TAC) conversion. The purpose of this study was to compare clinical and safety outcomes…
2018 American Transplant Congress
Renal-Sparing Protocol May Be Harmful If Performed Early Post-Heart Transplant
J. Patel, M. Johl, E. Kransdorf, M. Kittleson, S. Dimbil, R. Levine, D. Chang, L. Czer, J. Kobashigawa.
Cedars Sinai Medical Center, Los Angeles, CA.
Purpose: Calcineurin inhibitors (CNIs) are associated with nephrotoxicity. Renal sparing protocol (RSP) with CNI free regimen using mycophenolate and a proliferation signal inhibitor may improve…
2018 American Transplant Congress
Comparison of Temperatures for Optimal Preservation of Donor Kidneys during Oxygenated Pulsatile Perfusion
R. Bhattacharjee,¹ M. Richard-Mohamed,² A. Ruthirakanthan,³ R. Mayer,² S. Luke,³ H. Sharma,² M. TunAbraham,² B. Alharbi,² A. Haig,² P. Luke.^1,2,3
¹Matthew Mailing Centre for Translational Transplant Studies, London Health Sciences Centre, London, ON, Canada; ²Multi-Organ Transplant Program, London Health Sciences Centre, London, ON, Canada; ³Western University, Canada, London, ON, Canada.
Background. The current methods of preserving DCD renal allografts in either static cold solution or hypothermic pulsatile perfusion are unable to adequately protect the kidney…
2018 American Transplant Congress
The Renal Sparing Protocol after Heart Transplant That Keeps Giving
M. Kittleson, J. Patel, E. Kransdorf, S. Dimbil, R. Levine, D. Geft, D. Chang, L. Czer, R. Sharoff, J. Kobashigawa.
Cedars Sinai Medical Center, Los Angeles.
Purpose: Calcineurin inhibitors (CNI) such as cyclosporine and tacrolimus are known to cause chronic renal failure. As a result, programs have developed renal-sparing protocols (RSP)…
2018 American Transplant Congress
Change in Estimated Glomerular Filtration Rate Pre and Post Development of Donor-Specific Antibodies after Kidney Transplantation
B. Ho,¹ S. Montag,^1,2 H. Bhagat,³ K. Atiemo,¹ A. Daud,¹ R. Kang,¹ L. Zhao,^1,2 J. Schwartz,³ D. Ladner.¹
¹Northwestern University Transplant and Outcomes Research Collaborative (NUTORC), Chicago; ²Dept of Preventive Medicine, Northwestern University, Chicago; ³Astellas Pharma Global Development, Inc., Northbrook.
Formation of de novo donor-specific antibodies (dnDSA) against human leukocyte antigens contributes to inferior kidney transplant (KT) outcomes. We assessed the effect of dnDSA on…